University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial NC-HEM-07-5

A Double-Blind, Placebo-Controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, a Thrombopoietin Receptor Agonist, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who are Not Candidates for Anti-Viral Treatment with Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia.

Phase: Phase II
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Biological Response Modifier
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Howard Liebman, M.D.
Other Trial Staff:  Ilene Weitz, D.M., Melissa Peralta, D.M., Teresa Olea, R.N., Leslie Posadas, Coordinator

Staff may log in to see study documents.

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.